Kevin Bunker

Lengo Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Menlo Park, CA.

RetroSense Therapeutics LLC provides biotechnology services. It offers gene therapies to restore vision in patients suffering from blindness due to retinitis pigmentosa and advanced dry age-related macular degeneration. The company was founded by Sean Ainsworth in 2009 and is headquartered in Ann Arbor, MI.

Matrix Capital Management Co. LP (Matrix) is an independent registered investment adviser and hedge fund manager headquartered in Waltham, Massachusetts. The firm was founded by David E. Goel and Paul J. Ferri in 1999. Matrix serves as the manager or management firm, as the case may be, with discretionary investment authority to private pooled investment vehicles, the securities of which are offered to investors on a private placement basis.

Oncternal Oncology, Inc. is a clinical-stage oncology company, which engages in the development of novel therapies for both rare and common cancers. The company was founded by Lauren Otsuki and Cam L. Garner and is headquartered in San Diego, CA.

Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Tempus Labs, Inc. enagegs in the development of a platform that analyzes clinical and molecular data points focusing on cancer research. It connects physicians treatment options and relevant insights for patients based on their unique molecular profile and analytics and machine-learning algorithms. The firm offers genomic sequencing, clinical data structuring, image recognition, biological modeling, and time trial program. The company was founded by Bradley A. Keywell and Eric P. Lefkofsky in 2015 and is headquartered in Chicago, IL.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

Part of Eli Lilly & Co., Lilly Oncology is an American company dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. With over 50 years of experience, Lilly Oncology is committed to building on their heritage and improving the lives of all those affected by cancer worldwide.

Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA.

Cereius, Inc. develops novel radio-labeled therapeutics for treating solid tumor brain metastasis. The firm delivers new targeted classes of both radiologic diagnostics and radiotherapeutics for the treatment of cancers in the brain. The company was founded by Kimberly Blackwell and Michael R. Zalutsky in 2017 and is headquartered in Durham, NC.

Duke Cancer Institute is an organization that unites the academic and clinical communities of Duke University and the Duke University Health System. The non-profit company is based in Durham, NC and has subsidiaries in the United States. The company's main focus is to provide access to technologies, services, and scientific consultation through its Shared Resources.

Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA.

Solve Therapeutics, Inc. is an oncology-focused biopharmaceutical company that develops novel antibody-based therapies targeting tumor-specific antigens. The company is based in Belmont, CA, and has subsidiaries in the United States. The company's formation has reunited members of the former VelosBio Inc. team, a highly experienced group with a proven ability to rapidly advance innovative therapeutics that address unmet medical needs in the treatment of cancer. Solvetx has been actively pursuing discovery and development efforts at its state-of-the-art laboratory facilities. The company has licensed or generated targeting antibodies and nanobodies with ideal characteristics to serve as the backbones for antibody-based therapeutics and has rights to technology supporting the development of diagnostic and therapeutic antibody-radionuclide conjugates (ARCs). Solvetx is supported by a syndicate of sophisticated healthcare investors, including Ayurmaya Capital Management Fund (an affiliate of Matrix Capital Management), Decheng Capital, General, and Surveyor Capital (a Citadel company). The company was founded by David M. Johnson and has been led by him as the CEO since incorporation.

H.I.G. BioHealth Partners LLC (H.I.G. BioHealth Partners) is a private equity and venture capital subsidiary of H.I.G. Ventures LLC founded in 1993. The firm is headquartered in Miami, Florida with additional offices around the globe.

GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA.

DEM BioPharma, Inc. is an American company that pioneers the next generation of immunotherapeutics to eliminate tumors by targeting 'don't eat me' and 'eat me' signals on cancer cells, macrophages, and other myeloid effector cells. The company is based in Cambridge, MA. The proprietary CHOMP™ platform utilizes CRISPR-based functional genomic screens to discover and validate new signals that could enhance cancer cell elimination through increased phagocytosis. The company was founded by Longwood Fund and builds on groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders. Nenad Grmusa has been the CEO of the company since 2022.

Leerink Partners LLC is a full-service brokerage and investment banking firm headquartered in Boston, Massachusetts. The firm was founded by Jeffrey Leerink in 1995 and formerly known as SVB Securities LLC. They rebranded as Leerink Partners in 2023. The firm is a subsidiary of SVB Securities LLC. Leerink Partners provides institutional sales, equity research, institutional trading, and corporate finance and asset management services to the healthcare and technology industries. They offer superior execution capabilities in common stock, convertibles and derivatives with a singular focus on healthcare and a knowledge-led approach.

UBS AG's (NYSE: UBS) New York City-based wealth management arm is known as UBS Private Banking (US). The firm provides a range of customized wealth management products and services for private clients.

BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA.

Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation.

Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands.

CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany.

Eisai, Inc. manufactures pharmaceuticals products. It focuses on neurology, gastrointestinal disorders and oncology critical care. The company was founded in 1995 and is headquartered in Woodcliff Lake, NJ.